| abstract |
Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R 1 is fluoro, chloro, cyano or trifluoromethyl; R 2 is hydrogen, fluoro or chloro; R 3 is hydrogen, fluoro, chloro or trifluoromethyl; X is —CH 2 —, —S—, —S(═O)— or —S(═O) 2 —; one of Y and Y 1 is hydrogen and the other is —C(═O)R 4 , or —S(═O) 2 R 4 , or —CR 5 R 6 OR 7 or a heterocyclic group selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, furazanyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl and 1,3,5-triazinyl any of which may be optionally substituted; R 4 is an optionally substituted cyclic amino group having 5, 6 or 7 ring atoms which is linked to the carbonyl or sulfonyl through a ring nitrogen; R 5 and R 6 are independently hydrogen, (C 1 C 3 )alkyl, cyclopropyl, or R 5 and R 6 taken together with the carbon atom to which they are attached form a 3-6 membered cycloalkyl ring; and R 7 is optionally substituted (C 1 -C 6 )alkyl or (C 3 -C 6 )cycloalkyl, |